预约演示

更新于：2025-05-07

CHRNA9

更新于：2025-05-07

基本信息

别名

acetylcholine receptor, nicotinic, alpha 9 (neuronal)、cholinergic receptor nicotinic alpha 9 subunit、cholinergic receptor, nicotinic alpha 9

+ [7]

简介

Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840).

关联

项与 CHRNA9 相关的药物

GAT-2710

靶点

CHRNA9

作用机制

CHRNA9 agonists

在研机构

Bouvé College of Health Sciences

原研机构

Bouvé College of Health Sciences

在研适应症

慢性疼痛

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

1HA-78

靶点

CHRNA9

作用机制

CHRNA9 agonists

在研机构

Bouvé College of Health Sciences

原研机构

Bouvé College of Health Sciences

在研适应症

慢性疼痛

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

1HA-84

靶点

CHRNA9

作用机制

CHRNA9 agonists

在研机构

Bouvé College of Health Sciences

原研机构

Bouvé College of Health Sciences

在研适应症

慢性疼痛

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 CHRNA9 相关的临床结果

登录后查看更多信息

100 项与 CHRNA9 相关的转化医学

登录后查看更多信息

0 项与 CHRNA9 相关的专利（医药）

登录后查看更多信息

120

项与 CHRNA9 相关的文献（医药）

2025-04-29·Proceedings of the National Academy of Sciences

B cell–derived acetylcholine mitigates skin inflammation in mice through α9 nicotinic acetylcholine receptor–mediated signaling

Article

作者: Elia, Andrew J. ; Candi, Eleonora ; Haight, Jillian ; Ramamurthy, Nisha ; Melino, Gerry ; Helke, Simone ; Rugolo, Francesco ; Tobin, Chantal ; Berger, Thorsten ; Jafari, Soode Moghadas ; You-Ten, Annick ; Mak, Tak W. ; Foffi, Erica

Chronic inflammatory skin disorders are characterized by keratinocyte hyperproliferation and hyperactivation as well as immune cell infiltration. We investigated whether immune cell–derived acetylcholine (ACh) is a modulator of skin inflammation in mice. Here, we identify skin epithelial B cells as a key source of ACh that damps down inflammation. We used imiquimod (IMQ) to induce inflammatory skin disease (ISD) in mice lacking ACh production specifically in B cells (ChAT fl/fl;Mb1-Cre mice). Increased keratinocyte proliferation, epidermal thickening, and elevated levels of proinflammatory cytokines resulted. ACh binding to α9 nicotinic ACh receptor (encoded by Chrna9 ) expressed on wild-type mouse keratinocytes reduced their proliferation. Chrna9 -deficient mice exhibited the same exacerbated ISD phenotype as ChAT fl/fl;Mb1-Cre mice following IMQ induction. Our data suggest that B cell–derived ACh maintains skin homeostasis by modulating keratinocyte turnover and controlling immune-related inflammation. Therapeutic manipulation of this cholinergic pathway might mitigate both keratinocyte dysfunction and immune dysregulation in human patients, potentially pointing to treatments for ISDs such as psoriasis and related disorders.

2025-01-01·Heliyon

Identification and analysis of prognostic ion homeostasis characteristics in kidney renal clear cell carcinoma

Article

作者: Li, Liyang ; Zhang, Xiangmin ; Chu, Jian ; Ye, Maofei ; Qian, Xiongxian ; Zhao, Yong

Kidney renal clear cell carcinoma (KIRC), a prevalent primary malignant tumor within the urinary system, is characterized by significant heterogeneity. It has been shown that ion channels are important targets for anti-tumor therapy. In this study, we screened 70 selected KIRC related ion homeostasis genes with significant differential expression. We established diagnostic and prognostic models for 15 genes (PDK4, JPH4, ATP1A3, CCL7, CYP27B1, ABCB6, TNFSF11, MCHR1, TNNI3, ANGPTL3, Ednrb, SAA1, Chrna9, TMPRSS6, CCL14) by LASSO regression in the TCGA-KIRC cohort. We also provided a nomogram based on ion homeostasis for clinicians to explore the combined effect of the risk model on clinical variables. Patients in the low-risk group have a significant survival advantage. The potential clinical benefit of our predicted 15 gene signatures in clinical strategies was validated by Calibration Curves and DCA curves. Ultimately, the immune microenvironment and enrichment pathways were analyzed among individuals categorized as high-risk and low-risk. The predictable ion homeostasis-associated 15 gene signature established in this study predicts overall survival outcomes in patients with KIRC, to some extent helping clinicians to select personalized treatment regimens.

2024-11-01·Angiogenesis

The angiogenic role of the alpha 9-nicotinic acetylcholine receptor in triple-negative breast cancers

Article

作者: Chen, Michael ; Chang, Chun-Chao ; Rahayu, Sri ; Cheng, Chun-Chia ; Chuang, Kuo-Hsiang ; Kan, Tzu-Chun ; Hsu, Chun-Chun ; Chang, Jungshan ; Ochirbat, Sonjid ; Huang, Tzu-Hsuan

Nicotine acts as an angiogenic factor by stimulating endogenous cholinergic pathways. Several subtypes of nicotinic acetylcholine receptors (nAChRs) have been demonstrated to be closely correlated to the formation and progression of different types of cancers. Recently, several studies have found that nicotinic acetylcholine receptors α9 (α9-nAChRs) are highly expressed in breast tumors, especially in tumors derived from patients diagnosed at advanced stages. In vitro studies have demonstrated that activation of α9-nAChRs is associated with increased proliferation and migration of breast cancer. To study the tumor-promoting role of α9-nAChRs in breast cancers, we generated a novel anti-α9-nAChR and methoxy-polyethylene glycol (mPEG) bispecific antibody (α9 BsAb) for dissecting the molecular mechanism on α9-nAChR-mediated tumor progression. Unexpectedly, we discovered the angiogenic role of α9-nAChR in nicotine-induced neovascularization of tumors. It revealed α9 BsAbs reduced nicotine-induced endothelial cell tube formation, blood vessel development in Matrigel plug assay and angiogenesis in microtube array membrane murine model (MTAMs). To unbraid the molecular mechanism of α9-nAChR in nicotine-mediated angiogenesis, the α9 BsAbs were applied and revealed the inhibitory roles in nicotine-induced production of hypoxia-inducible factor-2 alpha (HIF-2α), vascular endothelial growth factor A (VEGF-A), phosphorylated vascular endothelial growth factor receptor 2 (p-VEGFR2), vascular endothelial growth factor receptor 2 (VEGFR2) and matrix metalloproteinase-9 (MMP9) from triple-negative breast cancer cells (MDA-MB-231), suggesting α9-nAChRs played an important role in nicotine-induced angiogenesis. To confirm our results, the shRNA targeting α9-nAChRs was designed and used to silence α9-nAChR expression and then evaluated the angiogenic role of α9-nAChRs. The results showed α9 shRNA also played an inhibitory effect in blocking the nicotine-induced angiogenic signaling. Taken together, α9-nAChR played a critical role in nicotine-induced angiogenesis and this bispecific antibody (α9 BsAb) may serve as a potential therapeutic candidate for treatments of the α9 positive cancers.

项与 CHRNA9 相关的新闻（医药）

2021-05-03

·医药合作投融资联盟

新锐-放射治疗和诊断公司完成1100万美元A轮融资

2021年4月28日，温哥华市，Alpha-9 Theranostics Inc.宣布完成1100万美元的A轮融资，以推进新型放射治疗和诊断产品组合的发展。Longitude Capital领导了此次融资，BVF Partners L.P.和内部人士的参与融资。董事会主席Simon Pimstone博士说：“我们很高兴Longitude和BVF在Alpha-9上进行投资。” “这些高质量的投资者对我们的信念是放射疗法和诊断学。” Longitude Capital的医学博士David Hirsch表示：“ Alpha-9是一家令人兴奋的公司，由该领域的领导者创立，拥有越来越多的新颖资产。我们相信放射治疗学有潜力兑现精准肿瘤学的希望，我们期待与Alpha-9小组合作，将多个项目推进临床试验。” 关于Alpha-9 Alpha-9 Theranostics是一家临床阶段的放射性药物公司，致力于开发针对实体和血液恶性肿瘤的成像和治疗分子。利用专有技术和公司的专业知识，这些差异化分子具有以有利的安全性显着延长患者生命的潜力。Alpha-9由不列颠哥伦比亚大学和不列颠哥伦比亚大学癌症研究人员创立，旨在改善受转移性癌症影响的患者的生活。关于Longitude Capital Longitude Capital是一家领先的医疗保健风险投资公司，投资于寻求改善临床结果，改善生活质量并提高医疗保健效率的变革性生物技术，医疗技术和健康解决方案公司。Longitude Capital成立于2006年，通过多种投资方式投资于私营和上市公司。经度资本在加州门洛帕克，康涅狄格州格林威治和马萨诸塞州波士顿设有办事处。版权声明：本文转自医药合作投融资联盟，如不希望被转载的媒体或个人可与我们联系，我们将立即删除 ↓↓点击下方图片报名药融圈近期活动↓↓▲6.17-18 · 重庆 · 免费 · 创新制剂及改良型新药峰会，火热报名中▲8.10-11 苏州国际博览中心 · 免费 · 第三届CMC-China 万人大会，火热报名中▲5.11-12 · 广州 · 免费 · 新药峰会，即将开始【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看